CALZF
PolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing hernia devices for hernia repair and tissue reinforcement products; NovoSorb Dermal Beta Cell Implant to host pancreatic islets in the skin; and NovoSorb drug elution depots. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q2 | 0.00 | $70M | -$2M |
| 2025 Q4 | 0.01 | $68M | $7M |
| 2024 Q2 | 0.00 | $60M | -$18M |
| 2024 Q4 | 0.00 | $56M | $1M |
| 2023 Q2 | 0.00 | $47M | $49,000 |
| 2023 Q4 | -0.00 | $36M | -$5M |
| 2022 Q2 | -0.01 | $29M | -$3M |
| 2022 Q4 | -0.00 | $23M | $951,700 |